Gene Therapy Market Size

Request Free Sample Copy

Report ID: 6234
Published Date: Sep 17, 2025
Report Format: PDF, PPT

Buy Now

Gene Therapy Market Outlook:

Gene Therapy Market size was over USD 8.32 billion in 2025 and is projected to reach USD 49 billion by 2035, witnessing around 19.4% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of gene therapy is evaluated at USD 9.77 billion.

The market is expanding due to the rise in cancer patients and deaths associated with the disease highlighting the need for effective therapeutic alternatives. The World Health Organization predicts that there will be over 35 million new cases of cancer in 2050, up 77% over the 20 million cases expected in 2022. Furthermore, WHO anticipated that high HDI nations will see the most absolute increases in incidence, with an extra 4.8 million new cases estimated in 2050 compared to estimates for 2022.

Browse key industry insights with market data tables & charts from the report:

Gene Therapy Market Size, Share, Growth & Industry Forecast 2035

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of gene therapy is evaluated at USD 9.77 billion.

The global gene therapy market size was worth over USD 8.32 billion in 2025 and is poised to witness a CAGR of over 19.4%, crossing USD 49 billion revenue by 2035.

The North America gene therapy market is anticipated to capture 37% share by 2035, driven by the presence of sophisticated infrastructure and availability of cutting-edge technologies.

Key players in the market include Novartis AG, Biogen Inc., Gilead Sciences, Inc., Bristol–Myers Squibb, Alnylam Pharmaceuticals, Sarepta Therapeutics, Orchard Therapeutics, Celgene Corporation.